Background: Cardiomyopathies are a rare cause of pediatric heart disease, but they are one of the leading causes of heart failure admissions, sudden death, and need for heart transplant in childhood. Reports from the Pediatric Cardiomyopathy Registry (PCMR) have shown that almost 40% of children presenting with symptomatic cardiomyopathy either die or undergo heart transplant within 2 years of presentation. Little is known regarding circulating biomarkers as predictors of outcome in pediatric cardiomyopathy.
Study design: The Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) study is a multi-center prospective study conducted by the PCMR investigators to identify serum biomarkers for predicting outcome in children with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). Patients less than 21 years of age with either DCM or HCM were eligible. Those with DCM were enrolled into cohorts based on time from cardiomyopathy diagnosis: categorized as new onset or chronic. Clinical endpoints included sudden death and progressive heart failure.
Results: There were 288 children diagnosed at a mean age of 7.2±6.3 years who enrolled in the PCM Biomarkers Study at a median time from diagnosis to enrollment of 1.9 years. There were 80 children enrolled in the new onset DCM cohort, defined as diagnosis at or 12 months prior to enrollment. The median age at diagnosis for the new onset DCM was 1.7 years and median time from diagnosis to enrollment was 0.1 years. There were 141 children enrolled with either chronic DCM or chronic HCM, defined as children ≥2 years from diagnosis to enrollment. Among children with chronic cardiomyopathy, median age at diagnosis was 3.4 years and median time from diagnosis to enrollment was 4.8 years.
Conclusion: The PCM Biomarkers study is evaluating the predictive value of serum biomarkers to aid in the prognosis and management of children with DCM and HCM. The results will provide valuable information where data are lacking in children.
Clinical trial registration nct01873976: https://clinicaltrials.gov/ct2/show/NCT01873976?term=PCM+Biomarker&rank=1.
Keywords: biomarkers; cardiomyopathy; heart failure; pediatrics.
Conflict of interest statement
Conflicts of Interest: None
The Pediatric Cardiomyopathy Registry: 1995-2007.Prog Pediatr Cardiol. 2008 Apr;25(1):31-36. doi: 10.1016/j.ppedcard.2007.11.006. Prog Pediatr Cardiol. 2008. PMID: 19343086 Free PMC article.
Survival Without Cardiac Transplantation Among Children With Dilated Cardiomyopathy.J Am Coll Cardiol. 2017 Nov 28;70(21):2663-2673. doi: 10.1016/j.jacc.2017.09.1089. J Am Coll Cardiol. 2017. PMID: 29169474 Free PMC article. Clinical Trial.
Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.Clin Cardiol. 2010 Jul;33(7):E24-8. doi: 10.1002/clc.20533. Clin Cardiol. 2010. PMID: 20641106 Free PMC article.
Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group.Cardiol Young. 2015 Aug;25 Suppl 2:140-53. doi: 10.1017/S1047951115000943. Cardiol Young. 2015. PMID: 26377721 Review.
[Prognosis of hypertrophic and dilated cardiomyopathy].Nihon Rinsho. 2000 Jan;58(1):86-92. Nihon Rinsho. 2000. PMID: 10885294 Review. Japanese.